Related resources
Full-text held externally
- PMID: 21678331
- UKPMCID: 21678331
- DOI: 10.1002/14651858.CD001040.pub2
Search for item elsewhere
University researcher(s)
Academic department(s)
Adjuvant progestagens for endometrial cancer.
Martin-Hirsch, Pierre Pl; Bryant, Andrew; Keep, Sarah L; Kitchener, Henry C; Lilford, Richard
Cochrane database of systematic reviews (Online). 2011;(6):CD001040.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 21678331
- UKPMCID: 21678331
- DOI: 10.1002/14651858.CD001040.pub2
Abstract
BACKGROUND: Endometrial cancer is the most common genital tract carcinoma among women in developed countries, with most women presenting with stage 1 disease. Adjuvant progestagen therapy has been advocated following primary surgery to reduce the risk of recurrence of disease. OBJECTIVES: To evaluate the effectiveness and safety of adjuvant progestagen therapy for the treatment of endometrial cancer. SEARCH STRATEGY: We searched the Cochrane Gynaecological Cancer Group Trials Specilaised Register, Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2009. MEDLINE and EMBASE up to April 2009. SELECTION CRITERIA: Randomised controlled trials (RCTs) of progestagen therapy in women who have had surgery for endometrial cancer. DATA COLLECTION AND ANALYSIS: Two review authors independently abstracted data and assessed risk of bias. Risk ratios (RRs) comparing survival in women who did and did not receive progestagen were pooled in random effects meta-analyses. . MAIN RESULTS: Seven trials assessing 4556 women were identified. Three trials included women with stage one disease only, whereas four included women with more advanced disease. Meta-analysis of four trials showed that there was no significant difference in the risk of death at five years between adjuvant progestagen therapy and no further treatment (RR = 1.00, 95% CI 0.85 to 1.18). This conclusion is also robust to single trial analyses at 4 and 7 years and in one trial across all points in time using a hazard ratio (HR). There was also no significant difference between progestagen therapy and control in terms of the risk of death from endometrial cancer, cardiovascular disease and intercurrent disease. Relapse of disease appeared to be reduced by progestagen therapy in one trial (HR = 0.71, 95% CI 0.52 to 0.97 and 5 year RR = 0.74, 95% CI 0.58 to 0.96), but there was no evidence of a difference in disease recurrence in another trial at 7 years (RR = 1.34, 95% CI 0.79 to 2.27). AUTHORS' CONCLUSIONS: There is no evidence to support the use of adjuvant progestagen therapy in the primary treatment of endometrial cancer.